RxDoctor Payments Data

Thomas Perron, NP

Psychiatric/Mental Health · New York, NYNPI 1710179825

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 51 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$405
  • Lundbeck LLC$247
  • Johnson & Johnson$180
  • AbbVie$115
  • Axsome Therapeutics, Inc.$113
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • plus $208 from 6 others

What the payments were for

  • Food & beverage$1,23292%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,332 in reported general payments places this provider in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$19,648
Medicare patients
90
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$34,168
VraylarCariprazine Hcl11$17,644
Lurasidone Hcl25$7,520
Aripiprazole127$7,176
Paliperidone ErPaliperidone35$4,413
Haloperidol Decanoate24$1,272
Duloxetine Hcl56$1,257
Mirtazapine67$1,010
Bupropion XlBupropion Hcl61$890
Quetiapine Fumarate61$732
Gabapentin49$575
Trazodone Hcl90$573
Alprazolam37$521
Buspirone Hcl48$482
Divalproex Sodium41$464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$180$34,16812 claims
AbbVieVraylar$115$17,64411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →